A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae109 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2024. Verfasst von Hui-Jen Tsai und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. Hauptthemen laut MEDLINE: Oxaliplatin, Paclitaxel, Antineoplastic Combined Chemotherapy Protocols, Drug Combinations. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiwan Cooperative Oncology Group.
Abstract (Originalsprache)
Background
Oxaliplatin- and fluoropyrimidine-based triplet regimens have demonstrated feasibility and efficacy in the treatment of upper gastrointestinal (UGI) cancers. Herein, we evaluate the feasibility and preliminary efficacy of biweekly nab-paclitaxel plus oxaliplatin and S-1/leucovorin (SOLAR) in chemonaïve UGI cancers.
Methods
A 3 + 3 phase 1 study was conducted to determine the maximal tolerated dose (MTD) of oxaliplatin in SOLAR (nab-paclitaxel [150 mg/m2 in D1], oxaliplatin [60, 75, or 85 mg/m2 in D1], and oral S-1/leucovorin [35 mg/m2 and 30 mg bid from D1 to D7]). The secondary endpoints were overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.
Results
Thirteen and 6 accruals were in the dose-escalation and MTD expansion cohorts, respectively. One of 6 patients at level III experienced dose-limiting toxicity (grade 3 diarrhea), which revealed that the MTD of oxaliplatin was 85 mg/m2. After a mean of 15.9 cycles of treatment, the most common treatment-related grade 3/4 toxicities were neutropenia (57.9%) and diarrhea (21.1%). The ORR was 63.2%. The median PFS and OS were 12.5 and 24.7 months, respectively.
Conclusion
The current study revealed the MTD of oxaliplatin and demonstrated the preliminary efficacy of SOLAR in UGI cancers, which deserves further investigation. ClinicalTrials.gov Identifier NCT03162510
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.
- National Taiwan University Cancer Center, Taipei, Taiwan.
Förderung
- Taiwan Cooperative Oncology Group
Zitieren
APA
Tsai, H. J., Yang, S. H., Hsiao, C. F., Kao, H. F., Su, Y. Y., Shan, Y. S., Yen, C. J., Du, J. S., Hsu, C., Wu, I. C., & Chen, L. T. (2024). A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study. The Oncologist. https://doi.org/10.1093/oncolo/oyae109
Vancouver
Tsai HJ, Yang SH, Hsiao CF, Kao HF, Su YY, Shan YS, et al. A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study. The Oncologist. 2024. doi:10.1093/oncolo/oyae109
BibTeX
@article{Tsai2024,
author = {Tsai, Hui-Jen and Yang, Shih-Hung and Hsiao, Chin-Fu and Kao, Hsiang-Fong and Su, Yung-Yeh and Shan, Yan-Shen and Yen, Chia-Jui and Du, Jeng-Shiun and Hsu, Chiun and Wu, I-Chen and Chen, Li-Tzong},
title = {A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae109}
}
EUVIMED